In transurethral microwave therapy (TUMT), an instrument (called an antenna) that sends out microwave energy is inserted through the urethra to a location inside the prostate. Microwave energy is then used to heat the inside of the prostate. Cooling fluid is circulated around the microwave antenna to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate, a temperature sensor is inserted into the man's rectum during the procedure. If the temperature in the rectum increases too much, the treatment is turned off automatically until the temperature goes back down.
The temperature becomes high enough inside the prostate to kill some of the tissue. As this part of the prostate heals, it shrinks, reducing the blockage of urine flow.
Microwave therapy is also known as cooled thermal therapy or by the name of the equipment used.
You are typically able to go home after surgery. You may not be able to urinate and may need catheterization to drain your bladder. For most men, this lasts for a week or less.
You can typically return to work 1 to 2 days after treatment. Sexual activity can be resumed 1 to 2 weeks after surgery.
TUMT is done to help relieve the symptoms of benign prostatic hyperplasia (BPH). It is an option for men who want more than medicines for treatment of their symptoms.
One study showed that TUMT improved symptoms and urine flow better than the alpha-blocker terazosin when checked 6 months and 18 months later.1
Studies find that TUMT does not improve symptoms and urine flow as much as TURP does.1
The main complications of TUMT include:1
Men who have TUMT don't lose as much blood as men who have TURP. So men who have TUMT have less need for a blood transfusion. They also have less of a problem with retrograde ejaculation than men who have TURP.
Reports have warned that in a small number of cases the procedure has caused serious injuries and complications, including damage to the penis and urethra. Injuries have required urostomies, partial amputation of the penis, and other procedures. In December 2000, the U.S. Food and Drug Administration (FDA) issued a warning about these injuries.
Most trials using TUMT have been limited by a small number of participants, a short length of time of study, and limited follow-up with the participants after the trial ended.
This procedure is not recommended for men who have prostate cancer or for men who are suspected of having prostate cancer.
Last Revised: March 5, 2012
To learn more visit Healthwise.org
© 1995-2013 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.